Looking Back Through the MIST: A Perspective of Evolving Strategies and Key Focus Areas for Metabolite Safety Analysis

• Clarke NJ , RingdenD, KorfmacherWA, CoxKA. Systematic LC/MS metabolite identification in drug discovery. Anal. Chem. 73, 430A–439A (2001).
   PubMed Web of Science ®Google Scholar
• Korfmacher WA , BryantMS, CoxKAet al. Strategies for optimising the use of mass spectrometry for drug metabolism participation in new drug discovery. Adv. Mass Spectrom. 15, 679–680 (2001).
   Google Scholar
• Kostainien R , KotiahoT, KuuranneT, AuriolaS. Liquid chromatography/atmospheric pressure ionisation–mass spectrometry in drug metabolism studies. J. Mass Spectrom. 38, 357–372 (2003).
   PubMed Web of Science ®Google Scholar
• Watt AP , Mortishire-SmithRJ, GerhardU, ThomasT. Metabolite identification in drug discovery. Drug Discov. Dev. 6, 57–65 (2003).
   Google Scholar
• Baillie TA , CayenMN, FoudaHet al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188–196 (2002).
   PubMed Web of Science ®Google Scholar
• Hastings KL , El-HageJ, JacobsA, LeightonJ, MorseD, OsterbergRE. Letter to the Editor. Toxicol. Appl. Pharmacol. 190, 91–92 (2003).
   PubMed Web of Science ®Google Scholar
• Baillie TA , CayenMN, FoudaHet al. Letter to the Editor. Reply. Toxicol. Appl. Pharmacol. 190, 93–94 (2003).
   Web of Science ®Google Scholar
• Smith DA , ObachRS. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409–1417 (2005).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Metabolites and safety: what are the concerns and how should we address them? Chem. Res. Toxicol. 19, 1570–1579 (2006).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , LinJH, BaillieT. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143–152 (2006).
   PubMed Web of Science ®Google Scholar
• Guengerich FP . Safety assessment of stable drug metabolites. Chem. Res. Toxicol. 19, 1559–1560 (2006).
   Web of Science ®Google Scholar
• Humphreys WG , UngerSE. Safety assessment of drug metabolites: characterisation of chemically stable metabolites. Chem. Res. Toxicol. 19, 1564–1569 (2006).
   PubMed Web of Science ®Google Scholar
• Prakash C , SharmaR, GleaveM, NeddermanANR. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr. Drug Metab. 9, 952–964 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar S , KasshunK, Tschirret-GuthRA, MitreK, BaillieT. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr. Opin. Drug Discov. Dev. 11, 43–52 (2008).
   PubMed Web of Science ®Google Scholar
• Baillie T . Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129–137 (2008).
   PubMed Web of Science ®Google Scholar
• Walker D , BradyJ, DalvieDet al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem. Res. Toxicol. 22, 1653–1662 (2009).
   PubMed Web of Science ®Google Scholar
• Nedderman ANR . Metabolites in safety testing: metabolite identification strategies in discovery and development. Biopharm. Drug Dispos. 30, 153–162 (2009).
   PubMed Web of Science ®Google Scholar
• Lappin G , StevensL. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Exp. Opin. Drug Metabol. Toxicol. 4, 1021–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Seymour M . The best model for humans is human – how to accelerate early drug development safely. Altern. Lab Anim. 37, 61–65 (2009)
   PubMed Web of Science ®Google Scholar
• Leclerq L , CuyckensF, MannensGSJ, de Vries R, Timmerman P, Evans DC. Which metabolites have we MIST? Retrospective analysis, practical aspects and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22, 280–293 (2009).
   PubMed Web of Science ®Google Scholar
• Baillie TA . Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem. Res. Toxicol. 22, 263–266 (2009)
   PubMed Web of Science ®Google Scholar
• Zhu M , ZhangD, ZhangH, ShyuWC. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Biopharm. Drug Dispos. 20, 163–184 (2009).
   Google Scholar
• Zhuang H , ZhangD, RayK. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J. Mass Spectrom. 38, 1110–1112 (2003).
   PubMed Web of Science ®Google Scholar
• Zhu P , TongW, AltonK, ChowdhuryS. An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC–MS data. Anal. Chem. 81, 5910–5917 (2009).
   PubMed Web of Science ®Google Scholar
• Wishart DS . Applications of metabolomics in drug discovery and development. Drugs RD9, 307–322 (2008).
   PubMed Web of Science ®Google Scholar
• Alex A , HarveyS, ParsonsT, PullenFS, WrightP, RileyJ-A. Can density functional theory (DFT) be used as an aid to a deeper understanding of tandem mass spectrometric fragmentation pathways? Rapid Commun. Mass Spectrom. 23, 2619–2627 (2009).
   PubMed Web of Science ®Google Scholar
• Dear GJ , JamesAD, SardaS. Ultra-performance liquid chromatography coupled to linear ion trap mass spectrometry for the identification of drug metabolites in biological samples. Rapid Commun. Mass Spectrom. 20, 1351–1360 (2006).
   PubMedGoogle Scholar
• Mukhopadhyay R . IMS/MS: its time has come. Anal. Chem. 80, 7918–7920 (2008).
   PubMed Web of Science ®Google Scholar
• Lundahl A , LennernaesH, KnutsonL, BondessonU, HedelandM. Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos. 37, 2008–2017 (2009).
   PubMed Web of Science ®Google Scholar
• Hino F , DolphinD. The biomimetic oxidation of dieldrin using polyhalogenated metalloporphyrins. Chem. Commun. (Camb.). 7, 629–630 (1999).
   Google Scholar
• Akagah B , LormierAT, FournetA, FigadereB. Oxidatin of antiparasitic 2-substituted quinolines using metalloporphyrin catalysts: scale-up of a biomimetic reaction for metabolite production of drug candidates. Org. Biomol. Chem. 6, 4494–4497 (2008).
   PubMed Web of Science ®Google Scholar
• Li W , RozzellD, KambourakisS, MayhewM. Biosynthesis of drug metabolites. Biocatal. Pharm. Ind. 183–211 (2009).
   Google Scholar
• Tahara K , NishikawaT, HattoriY, LijimaS, KounoY, AbeY. Production of a reactive metabolite of troglitazone by electrochemical oxidation performed in nonaqueous medium. J. Pharm. Biomed. Anal. 50, 1030–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Johansson T , JurvaU, GroenbergG, WeidolfL, MasimirembwaC. Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry and NMR. Drug Metab. Dispos. 37, 571–579 (2009).
   PubMed Web of Science ®Google Scholar
• De Boer AR , LetzelT, Van Elswijk DA, Lingeman H, Niessen WMA, Irth H. On-line coupling of high-performance liquid chromatography to a continuous-flow enzyme assay based on electrospray ionization mass spectrometry. Anal. Chem. 76, 3155–3161 (2004).
   PubMed Web of Science ®Google Scholar
• De Boer AR , Alcaide-HidalgoJM, KrabbeJGet al. High-temperature liquid chromatography coupled on-line to a continuous-flow biochemical screening assay with electrospray ionization mass spectrometric detection. Anal. Chem. 77, 7894–7900 (2005).
   PubMed Web of Science ®Google Scholar
• Van Liempd SM , KoolJ, NiessenWMA, van Elswijk DE, Irth H, Vermeulen NPE. On-line formation, separation, and estrogen receptor affinity screening of cytochrome P450-derived metabolites of selective estrogen receptor modulators. Drug Metab. Dispos. 34, 1640–1649 (2006).
   PubMed Web of Science ®Google Scholar
• Van Liempd SM , KoolJ, MeermanJH, IrthH, VermeulenNP. Metabolic profiling of endocrine-disrupting compounds by on-line cytochrome P450 bioreaction coupled to on-line receptor affinity screening. Chem. Res. Toxicol. 20, 1825–1832 (2007).
   PubMed Web of Science ®Google Scholar
• De Vlieger JSB , KolkmanAJ, AmptKAMet al. Determination and identification of estrogenic compounds generated with biosynthetic enzymes using hyphenated screening assays, high resolution mass spectrometry and off-line NMR. J. Chromatogr. B878, 667–674 (20010).
   Google Scholar
• Wright P , MiaoZ, ShillidayB. Metabolite quantitation: detector technology and MIST implications. Bioanalysis1, 831–845 (2009).
   PubMed Web of Science ®Google Scholar
• Císař P , NobilisM, VybíralováZet al. Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection. J. Pharm. Biomed. Anal. 37, 1059–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Vishwanathan K , BabalolaK, WangJet al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 2, 311–322 (2009).
   Google Scholar
• Martino R , GilardV, DesmoulinF, Malet-MartinoM. Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative In vitro metabolic studies of fluorinated or phosphorylated drugs. J. Pharm. Biomed. Anal. 38, 871–891 (2005).
   PubMed Web of Science ®Google Scholar
• Espina R , YuL, WangJet al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299–310 (2009).
   PubMed Web of Science ®Google Scholar
• Dear GJ , RobertsAD, BeaumontC, NorthSE. Evaluation of preparative high performance liquid chromatography and cryoprobe–nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chromatogr. B876, 182–190 (2008).
   PubMed Web of Science ®Google Scholar
• Skordi E , WilsonID, LindonJC, NicholsonJK. Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism. Xenobiotica34, 1075–1089 (2004).
   PubMed Web of Science ®Google Scholar
• Walker GS , O’ConnellTN. Comparison of LC-NMR and conventional NMR for structure elucidation in drug metabolism studies. Exp. Opin. Drug Metab. Toxicol. 4, 1295–1305 (2008).
   PubMed Web of Science ®Google Scholar
• Godejohann M , Tseng L-H, Braumann U, Fuchser J, Spraul M. Characterization of a paracetamol metabolite using on-line LC–SPE–NMR–MS and a cryogenic NMR probe. J. Chromatogr. A1058, 191–196 (2004).
   PubMed Web of Science ®Google Scholar
• Corcoran O , SpraulM. LC-NMR-MS in drug discovery. Drug Discovery Today 8, 624–631 (2004).
   Google Scholar
• Emwas A-H , SaundersM, LudwigC, GuentherUL. Determinants for optimal enhancement in ex site DNP experiments. Appl. Magn. Reson. 34, 483–494 (2008).
   Web of Science ®Google Scholar
• Roth M , BargonJ, SpiessHW, KochA. Parahydrogen induced polarization of barbituric acid derivatives: 1H hyperpolarization studies. Magn. Reson. Chem. 48, 713–717 (2008).
   Google Scholar
• Wishart DS . Quantitative metabolomics using NMR. Trends Anal. Chem. 27, 228–237 (2008).
   Web of Science ®Google Scholar
• Reynolds G , WilsonM, PeetA, ArvanitisTN. An algorithm for the automated quantitation of metabolites in In vitro signals. Magn. Reson. Med. 56, 1211–1219 (2006).
   PubMed Web of Science ®Google Scholar
• Gammelgaard B , HansenHR, SturupS, MollerC. The use of inductively coupled plasma mass spectrometry in drug metabolism studies. Exp. Opin. Drug Metab. Toxicol. 4, 1187–1207 (2008).
   PubMed Web of Science ®Google Scholar
• Smith C , JensenBP, WilsonID, Abou-ShakraF, CrowtherD. High-performance liquid chromatography/inductively coupled plasma mass spectrometry and tandem mass spectrometry for the detection of carbon containing compounds. Rapid Commun. Mass Spectrom. 18, 1487–1492 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen BP , SmithC, WilsonID, WeidolfL. Sensitive sulphur-specific detection of omeprazole metabolites in rat urine by high-performance liquid chromatography/inductively coupled plasma mass spectrometry. Rapid Commun. Mass Spectrom. 18, 181–183 (2004).
   PubMed Web of Science ®Google Scholar
• Duckett CJ , LindonJC, WalkerH, Abou-ShakraF, WilsonID, NicholsonJK. Metabolism of 3-chloro-4-fluoroaniline in rat using [14C]-radio labelling, 19F-NMR spectroscopy, HPLC–MS/MS, HPLC–ICPMS and HPLC–NMR. Xenobiotica36, 59–77 (2006).
   PubMed Web of Science ®Google Scholar
• Jensen BP , GammelgaardB, HansenSH, AndersenJV. HPLC–ICP–MS compared with radiochemical detection for metabolite profiling of 3H-bromahexine in rat urine and faeces. J. Anal. At. Spectrom. 20, 204–209 (2005).
   Web of Science ®Google Scholar
• Duckett CJ , BaileyNJC, WalkerHet al. Quantitation in gradient high performance liquid chromatography/inductively coupled mass spectrometry investigated using diclofenac and chloroprozamine. Rapid Commun. Mass Spectrom. 16, 245–247 (2002).
   PubMed Web of Science ®Google Scholar
• De Wolf K , BalcaenL, Van de Walle E, Cuyckens F, Vanhaecke F. A comparison between HPLC–dynamic reaction cell–ICP–MS and HPLC–sector field–ICP–MS for the detection of glutathione-trapped reactive drug metabolites using clozapine as a model compound. J. Anal. At. Spectrom. 25, 419–425 (20010).
   Google Scholar
• Vogel JS , TurteltaubKW. Bioanalytical application of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6, 991–2007 (2000).
   PubMed Web of Science ®Google Scholar
• Garner RC . Accelerator mass spectrometry in pharmaceutical research and development – a new ultrasensitive analytical method for isotope measurement. Curr. Drug Metab. 1, 205–230 (2000).
   PubMed Web of Science ®Google Scholar
• Buchholz BA , DuekerSR, LinY, CliffordAJ, VogelJS. Methods and application of HPLC–AMS. Nucl. Instrum. Methods Phys. Res. B. 172, 910–914 (2000).
   Web of Science ®Google Scholar
• Barker J , GarnerRC. Biomedical applications of accelerator mass spectrometry–isotope measurements at the level of the atom. Rapid Commun. Mass Spectrom. 13, 285–293 (1999).
   PubMed Web of Science ®Google Scholar
• Garner RC . Less is more: the human microdosing concept. Drug Discovery Today10, 449–451 (2005).
   PubMed Web of Science ®Google Scholar
• Garner RC , GorisI, LaenenAAEet al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study – experience with 14C-labelled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30, 823–830 (2002).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Metabolites in Safety Testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22, 267–279 (2009).
   PubMed Web of Science ®Google Scholar
• Martignoni M , GroothuisGM, De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Exp. Opin. Drug Metabol. Toxicol. 2, 875–894 (2006).
   PubMed Web of Science ®Google Scholar
• Zuber R , AnzenbacherovaE, AnzenbacherP. Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 6, 189–198 (2002).
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U , WachsmuthH. Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug Metab. Dispos. 29, 1343–1348 (2001).
   PubMed Web of Science ®Google Scholar
• Klieber S , HuglaS, NgoRet al. Contribution of the N-glucuronidation pathway to the overall In vitro metabolic clearance of midazolam in humans. Drug Metab. Dispos. 36, 851–862 (2008).
   PubMed Web of Science ®Google Scholar
• Kaye B , OffermanJL, ReidJL, ElliottHL, HillisWS. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica14, 935–945 (1984)
   PubMed Web of Science ®Google Scholar
• Kaye B , RanceDJ, WaringL. Oxidative metabolism of carbazeran In vitro by liver cytosol of baboon and man. Xenobiotica15, 237–242 (1985).
   PubMed Web of Science ®Google Scholar
• Bruck M , LiQ, LamgJG, TukeyRH. Characterisation of rabbit UDP-glucuronosyltransferase UGT1A7: tertiary amine glucuronidation is catalysed by UGT1A7 and UGT1A4. Arch. Biochem. Biophys. 348, 357–364 (1997).
   PubMed Web of Science ®Google Scholar
• Sugihara K , KitamuraS, TatsumiK. Strain differences of liver aldehyde oxidase activity in rats. Biochem. Mol. Biol. Int. 37, 861–869 (1995).
   PubMedGoogle Scholar
• Abel S , RussellD, WhitlockLA, RidgwayCE, NeddermanANR, WalkerDK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br. J. Clin. Pharmacol. 65, 60–67 (2008).
   PubMed Web of Science ®Google Scholar
• Walker DK , AbelS, CombyP, MuirheadGJ, NeddermanANR, SmithDA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33, 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Vourvahis M , GleaveM, NeddermanANRet al. Excretion and metabolism of lersivirine (UK-453,061), a next-generation NNRTI, following administration of [14C] lersivirine to healthy volunteers. Drug Metab. Dispos. DOI: 10.1124/dmd.109.031252 (In Press).
   Google Scholar
• Atrakchi AH . Interpretation and considerations on the safety evaluation of human drug metabolites. Chem. Res. Toxicol. 22, 1217–1220 (2009).
   PubMed Web of Science ®Google Scholar
• Robison TW , JacobsA. Metabolites in safety testing. Bioanalysis1, 1193–1200 (2009).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA. Guidance for Industry. Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar
• Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (CPMP/ICH/286/95) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073250.pdf (Accessed June2009).
   Google Scholar